These results collectively indicate that diminished FOXA1 expression is associated with a reduced chemotherapeutic response to cisplatin in NPC cells, highlighting the significance of FOXA1 in the modulation of drug sensitivity. This evidence concerns the gene FOXA1 and nasopharyngeal carcinoma.